Aptevo Therapeutics Inc. (APVO) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 26.9 (OVERSOLD (<32))
20D Institutional Volume Accumulation (±12.5% realized swing band)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While APVO currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.85) and Max Pain ($1.43) forces dealer call-delta covering toward $29.48.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Aptevo Therapeutics Inc. (APVO) surged +4.62% to $1.36, trading at 2% of its 52-week range ($1.25 – $28.08). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
By David Bautz, PhD NASDAQ: APVO READ THE FULL APVO RESEARCH REPORT Business Update 21% Stem Cell Transplantation Rate for Mipletamig Combination Therapy On October 26, 2026, Aptevo Therapeutics, Inc. (APVO) announced th
(Nasdaq:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced that ten patients with newly diagnosed acute myeloid leukemia (AML) have advanced to allo
Ten patients initially deemed unfit for intensive chemotherapy proceeded to stem cell transplantTransplant rate compares favorably with historical standard-of-care experience, adding to growing clinical evidence
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on APVO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for APVO. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Aptevo Therapeutics Inc. (APVO) ranks #465 by composite RQD confidence (46/100, grade D) and #989 by equity capitalization ($2.5M). Within this direct 5-issuer industry benchmark cohort, APVO leads on earnings valuation at N/A trailing P/E, while SBFM leads on capital efficiency and profitability with -21.4% ROIC and 33.8% gross margin. APVO currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| APVO
ACTIVE
Aptevo Therapeutics Inc. | D | 46/100 | — | — | -35.0% | +4.62% | $2.5M | Benchmark Subject |
| SILO Silo Pharma Inc. | E | 19/100 | — | 38.6% | -35.0% | -6.72% | $2.4M | /silo-vs-apvo → |
| SBFM Sunshine Biopharma Inc. | D | 44/100 | — | 33.8% | -21.4% | +7.07% | $2.5M | /sbfm-vs-apvo → |
| PRFX PRF Technologies Ltd. | D- | 39/100 | — | -30.0% | -35.0% | -3.86% | $2.6M | /prfx-vs-apvo → |
| HCWB HCW Biologics Inc. | E | 27/100 | — | 20.0% | -35.0% | -3.28% | $2.6M | /hcwb-vs-apvo → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aptevo Therapeutics Inc. (APVO) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$26.0M, operating cash flow of -$25.6M, and free cash flow of -$25.6M (-7.6% YoY). On the balance sheet, APVO closed FY2025 with $27.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$26.0M | -$25.6M | -$25.6M | $27.2M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$24.1M | -$23.8M | -$23.8M | $15.6M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$17.4M | -$11.7M | -$11.7M | — | — |
As of 2026-11-01, Aptevo Therapeutics Inc. (NASDAQ: APVO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $1.36 (+4.62% 1D, market cap $2.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, APVO ranks #465 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APVO carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SILO (Silo Pharma Inc.) holds a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $2.4M) and SBFM (Sunshine Biopharma Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -21.4%, cap $2.5M). Among the 5-stock peer group, APVO leads on earnings multiple (N/A) while SBFM leads on capital efficiency (-21.4% ROIC).
Per APVO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001671584), Aptevo Therapeutics Inc. generated $0 in revenue, -$26.0M in net income, and -$25.6M in free cash flow against $27.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
APVO last traded at $1.36 (+4.62% on volume of 58,518 shares), positioning the stock -26.49% below its 50-day simple moving average ($1.85) and -68.88% below its 200-day simple moving average ($4.37). Across its 52-week range of $1.25 to $28.08, APVO sits at the 0.4% percentile with a 14-day RSI of 26.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.19 to $1.53).
Why APVO Stock surged +4.62% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.